CHRS
NASDAQCoherus Oncology Inc.
News · 26 weeks37+600%
2026-03-012026-08-23
Mix2190d
- Insider9(43%)
- SEC Filings8(38%)
- Other1(5%)
- Earnings1(5%)
- Offering1(5%)
- Dividends1(5%)
Latest news
25 items- PRCoherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the "CVRs"), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September 30, 2026 (the "Record Date"). The distribution date for the CVRs (the "Distribution Date")
- SECCoherus Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form S-8 filed by Coherus Oncology Inc.S-8 - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form 10-Q filed by Coherus Oncology Inc.10-Q - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the second quarter 2026, and provided an overview of recent business highlights. "During the second quarter we continued to pursue our science-driven clinical development strategy, creating multiple avenues for long-term valu
- PRCoherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight Time. To access the conference call, please pre-register through the fol
- PRCoherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. "We are excited to partner with Zumutor Biologics on the development of LOQTORZI with ZM0008 as a
- SECCoherus Oncology Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- INSIDERDirector Satvat Ali J. was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Karachun Rita A was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Newcomer Lee Nisley was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Ryan Michael Lee was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector O'Donnell-Tormey Jill was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Wahlstrom Mats was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Newton Charles W. was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Lanfear Dennis M4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECSEC Form 10-Q filed by Coherus Oncology Inc.10-Q - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the first quarter
CHRS FAQ
7 questionsWhat does Coherus Oncology Inc. do?
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and...Where does CHRS stock trade?
Coherus Oncology Inc. (CHRS) is listed on NASDAQ.What sector and industry is CHRS in?
Coherus Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Coherus Oncology Inc. go public?
Coherus Oncology Inc. (CHRS) completed its IPO in 2014.What are analysts saying about CHRS?
Coherus Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1200.00 price target on 2026-05-11.What companies are similar to CHRS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare CHRS side-by-side with any of them on Quantisnow.How can I track CHRS on Quantisnow?
Quantisnow aggregates Coherus Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CHRS to receive live email and push alerts on every new disclosure.